pharma services

Research, development and manufacturing done for drug makers under contract.

Industry · 7 companies · 3 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • IAM Iambic Therapeutics, Inc.

    Sells it“In our Discovery Collaboration partnership model, such as our partnerships with AbbVie, Takeda, and Lundbeck, we use our molecular superintelligence platform for the development of drug candidates on specified disease-driving targets.”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • MRNA Moderna

    Supplies it 2%, $31.0M a quarter“Cost of sales was 24% of net product sales plus stand-ready manufacturing revenue in Q3, versus 21%; for 9M it was 75% versus 34%.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • MYGN Myriad Genetics

    Sells it“As part of our Cancer Care Continuum strategy, we also plan to expand the number of biopharma partners we serve with services including biomarker identification and validation, companion diagnostic test development and regulatory registration, as well as companion diagnostic test commercialization.”

    Latest 8-KExecutive pay ·

    One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.

  • PFE Pfizer

    Sells it 2%, $1.3B a year“PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • SDGR Schrödinger, Inc.

    Sells it 21%, $54.8M a year“We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • TMO Thermo Fisher Scientific

    Sells it, part of Service, Laboratory Products and Biopharma Services“Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals.”

    Latest 8-KLeadership change ·

    Executive Vice President Michael D. Shafer will retire effective Dec. 31, 2026.

  • TWST Twist Bioscience

    Sells it, part of DNA Synthesis And Protein Solutions“Through DNA Synthesis and Protein Solutions, we offer end-to-end solutions for therapeutic drug discovery including DNA synthesis, protein expression, antibody characterization and biologics discovery solutions.”

    Latest 10-KFY2026Positive ·

    AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.

    • Revenue$459.4MYoY +22.0%
    • Net income−$130.2MYoY −67.6%

Feedback